DeepMed Research

SANTEN PHARMACEUTICAL CO., LTD.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public

Established: 1890-01-01

Employees: 3.7K

Market Cap: $4.5B

Website: http://www.santen.co.jp

Clinical Trials

A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

Phase 3

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: DE-114 ophthalmic solution

First Posted Date: 2011-06-01

Last Posted Date: 2014-10-06

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 130

Registration Number: NCT01363713

Locations: 🇯🇵
Santen study sites, Osaka, Japan

DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open Angle Glaucoma or Ocular Hypertension

Interventions: Drug: DE-111 ophthalmic solution

First Posted Date: 2011-04-27

Last Posted Date: 2015-06-15

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 148

Registration Number: NCT01343082

Locations: 🇯🇵
Santen study sites, Osaka, Japan

DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

Phase 3

Completed

Conditions: Ocular Hypertension
Open Angle Glaucoma

Interventions: Drug: DE-111 ophthalmic solution
Drug: Tafluprost ophthalmic solution 0.0015%
Drug: Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%

First Posted Date: 2011-04-26

Last Posted Date: 2015-06-15

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 489

Registration Number: NCT01342081

Locations: 🇯🇵
Santen study sites, Osaka, Japan

DE-111 Against Timolol Ophthalmic Solution 0.5%

Phase 3

Completed

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Timolol ophthalmic solution 0.5%
Drug: DE-111 ophthalmic solution
Drug: Placebo ophthalmic solution

First Posted Date: 2011-04-26

Last Posted Date: 2015-07-10

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 166

Registration Number: NCT01342094

Locations: 🇯🇵
Santen study sites, Osaka, Japan

Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Phase 3

Completed

Conditions: Dry Eye

Interventions: Drug: 0.1% sodium hyaluronate ophthalmic solution
Drug: 3% DE-089 ophthalmic solution

First Posted Date: 2010-11-15

Last Posted Date: 2014-08-13

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 332

Registration Number: NCT01240382

Locations: 🇯🇵
Santen study sites, Osaka, Japan

Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Phase 2

Completed

Conditions: Dry Eye

Interventions: Drug: DE-089 ophthalmic solution
Drug: Placebo ophthalmic solution

First Posted Date: 2010-08-26

Last Posted Date: 2014-08-13

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 320

Registration Number: NCT01189032

Locations: 🇯🇵
Santen study sites, Osaka, Japan

Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Not Applicable

Completed

Conditions: Dry Eye

Interventions: Drug: diquafosol ophthalmic solution
Drug: 0.1% sodium hyaluronate ophthalmic solution.

First Posted Date: 2010-04-12

Last Posted Date: 2012-11-14

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 400

Registration Number: NCT01101984

Locations: 🇸🇬
Singapore Eye Research Institute, Singapore, Singapore
🇨🇳
Eye & Ear Hospital of Fudan University, Shanghai, China

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Phase 2

Completed

Conditions: Persistent Corneal Epithelial Defect

Interventions: Drug: DE-105 ophthalmic solution
Drug: Placebo ophthalmic solution

First Posted Date: 2009-10-02

Last Posted Date: 2012-11-22

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 45

Registration Number: NCT00988494

Locations: 🇯🇵
Santen study sites, Osaka, Japan

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: DE-104 ophthalmic solution, low concentration
Drug: DE-104 ophthalmic solution, high concentration
Drug: DE-104 vehicle
Drug: DE-104 ophthalmic solution, medium concentration

First Posted Date: 2008-04-14

Last Posted Date: 2009-03-16

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Registration Number: NCT00657579

Locations: 🇯🇵
Osaka, Japan, Osaka, Japan

To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: DE-104 ophthalmic solution
Drug: DE-104 vehicle

First Posted Date: 2008-04-11

Last Posted Date: 2009-03-16

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Registration Number: NCT00656240

Locations: 🇯🇵
Osaka, Japan, Osaka, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy